164 related articles for article (PubMed ID: 34856153)
41. Pediatric cancer and Li-Fraumeni/Li-Fraumeni-like syndromes: a review for the pediatrician.
Giacomazzi CR; Giacomazzi J; Netto CB; Santos-Silva P; Selistre SG; Maia AL; Oliveira VZ; Camey SA; Goldim JR; Ashton-Prolla P
Rev Assoc Med Bras (1992); 2015; 61(3):282-9. PubMed ID: 26248253
[TBL] [Abstract][Full Text] [Related]
42. MIR605 rs2043556 is associated with the occurrence of multiple primary tumors in TP53 p.(Arg337His) mutation carriers.
Bandeira IC; Vieira IA; Andreis TF; Brussa Reis L; Macedo GS; Vianna FSL; Santos-Silva P; Palmero EI; Galvão HCR; Ramos CRN; Santiago KM; Achatz MI; da Costa AABA; Ashton-Prolla P
Cancer Genet; 2020 Jan; 240():54-58. PubMed ID: 31778928
[TBL] [Abstract][Full Text] [Related]
43. Estimating
Peng G; Bojadzieva J; Ballinger ML; Li J; Blackford AL; Mai PL; Savage SA; Thomas DM; Strong LC; Wang W
Cancer Epidemiol Biomarkers Prev; 2017 Jun; 26(6):837-844. PubMed ID: 28137790
[No Abstract] [Full Text] [Related]
44. New surveillance guidelines for Li-Fraumeni and hereditary TP53 related cancer syndrome: implications for germline TP53 testing in breast cancer.
Evans DG; Woodward ER
Fam Cancer; 2021 Jan; 20(1):1-7. PubMed ID: 32984917
[No Abstract] [Full Text] [Related]
45. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.
Olivier M; Goldgar DE; Sodha N; Ohgaki H; Kleihues P; Hainaut P; Eeles RA
Cancer Res; 2003 Oct; 63(20):6643-50. PubMed ID: 14583457
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of TP53 Pro72Arg and MDM2 SNP285-SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations.
Ponti F; Corsini S; Gnoli M; Pedrini E; Mordenti M; Sangiorgi L
Fam Cancer; 2016 Oct; 15(4):635-43. PubMed ID: 26956143
[TBL] [Abstract][Full Text] [Related]
47. Li-Fraumeni syndrome and the role of the p53 tumor suppressor gene in cancer susceptibility.
Akashi M; Koeffler HP
Clin Obstet Gynecol; 1998 Mar; 41(1):172-99. PubMed ID: 9504235
[TBL] [Abstract][Full Text] [Related]
48. Diagnosis of Li-Fraumeni Syndrome: Differentiating TP53 germline mutations from clonal hematopoiesis: Results of the observational AGO-TR1 trial.
Weber-Lassalle K; Harter P; Hauke J; Ernst C; Kommoss S; Marmé F; Weber-Lassalle N; Prieske K; Dietrich D; Borde J; Pohl-Rescigno E; Reuss A; Ataseven B; Engel C; Stingl JC; Schmutzler RK; Hahnen E
Hum Mutat; 2018 Dec; 39(12):2040-2046. PubMed ID: 30216591
[TBL] [Abstract][Full Text] [Related]
49. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
[TBL] [Abstract][Full Text] [Related]
50. Myelodysplastic syndromes arising in patients with germline TP53 mutation and Li-Fraumeni syndrome.
Talwalkar SS; Yin CC; Naeem RC; Hicks MJ; Strong LC; Abruzzo LV
Arch Pathol Lab Med; 2010 Jul; 134(7):1010-5. PubMed ID: 20586629
[TBL] [Abstract][Full Text] [Related]
51. Whole-genome sequencing analysis of phenotypic heterogeneity and anticipation in Li-Fraumeni cancer predisposition syndrome.
Ariffin H; Hainaut P; Puzio-Kuter A; Choong SS; Chan AS; Tolkunov D; Rajagopal G; Kang W; Lim LL; Krishnan S; Chen KS; Achatz MI; Karsa M; Shamsani J; Levine AJ; Chan CS
Proc Natl Acad Sci U S A; 2014 Oct; 111(43):15497-501. PubMed ID: 25313051
[TBL] [Abstract][Full Text] [Related]
52. The role of TP53 pathogenic variants in early-onset HER2-positive breast cancer.
Escudeiro C; Pinto C; Vieira J; Peixoto A; Pinto P; Pinheiro M; Santos C; Guerra J; Lisboa S; Santos R; Silva J; Leal C; Coimbra N; Lopes P; Ferreira M; Sousa AB; Teixeira MR
Fam Cancer; 2021 Jul; 20(3):173-180. PubMed ID: 33051812
[TBL] [Abstract][Full Text] [Related]
53. Cancer surveillance and distress among adult pathogenic TP53 germline variant carriers in Germany: A multicenter feasibility and acceptance survey.
Rippinger N; Fischer C; Haun MW; Rhiem K; Grill S; Kiechle M; Cremer FW; Kast K; Nguyen HP; Ditsch N; Kratz CP; Vogel J; Speiser D; Hettmer S; Glimm H; Fröhling S; Jäger D; Seitz S; Hahne A; Maatouk I; Sutter C; Schmutzler RK; Dikow N; Schott S
Cancer; 2020 Sep; 126(17):4032-4041. PubMed ID: 32557628
[TBL] [Abstract][Full Text] [Related]
54. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study.
Villani A; Tabori U; Schiffman J; Shlien A; Beyene J; Druker H; Novokmet A; Finlay J; Malkin D
Lancet Oncol; 2011 Jun; 12(6):559-67. PubMed ID: 21601526
[TBL] [Abstract][Full Text] [Related]
55. The Li-Fraumeni syndrome: an inherited susceptibility to cancer.
Evans SC; Lozano G
Mol Med Today; 1997 Sep; 3(9):390-5. PubMed ID: 9302689
[TBL] [Abstract][Full Text] [Related]
56. The Clinical and Molecular Profile of Lung Cancer Patients Harboring the
Lopes CDH; Antonacio FF; Moraes PMG; Asprino PF; Galante PAF; Jardim DL; de Macedo MP; Sandoval RL; Katz A; de Castro G; Achatz MI
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894716
[TBL] [Abstract][Full Text] [Related]
57. Genetic and functional studies of a germline TP53 splicing mutation in a Li-Fraumeni-like family.
Varley JM; Chapman P; McGown G; Thorncroft M; White GR; Greaves MJ; Scott D; Spreadborough A; Tricker KJ; Birch JM; Evans DG; Reddel R; Camplejohn RS; Burn J; Boyle JM
Oncogene; 1998 Jun; 16(25):3291-8. PubMed ID: 9681828
[TBL] [Abstract][Full Text] [Related]
58. Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic.
Bojadzieva J; Amini B; Day SF; Jackson TL; Thomas PS; Willis BJ; Throckmorton WR; Daw NC; Bevers TB; Strong LC
Fam Cancer; 2018 Apr; 17(2):287-294. PubMed ID: 28988289
[TBL] [Abstract][Full Text] [Related]
59. TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis.
Marcel V; Palmero EI; Falagan-Lotsch P; Martel-Planche G; Ashton-Prolla P; Olivier M; Brentani RR; Hainaut P; Achatz MI
J Med Genet; 2009 Nov; 46(11):766-72. PubMed ID: 19542078
[TBL] [Abstract][Full Text] [Related]
60. Analysis of Li-Fraumeni syndrome and Li-Fraumeni-like families for germline mutations in Bcl10.
Stone JG; Eeles RA; Sodha N; Murday V; Sheriden E; Houlston RS
Cancer Lett; 1999 Dec; 147(1-2):181-5. PubMed ID: 10660104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
